Pregnancy induced hypertension (PIH) is the most common complication during pregnancy and it affects up to 12% of pregnancies. It is the leading cause of maternal and fetal morbidity and mortality (1). Sildenafil is a potent and selective inhibitor of cGMP .which results in increased levels of cGMP, leading to smooth muscle relaxation thus mediating improved uteroplacental perfusion and increased fetal growth (12). Objectives:This study is to evaluate effect of sildenafil citrate on fetal growth and Doppler indices in treatment of pregnancy induced hypertension Setting:Department of Obstetrics &Gynecology, Beni-Suef University Hospital. Methods:Patients were divided into two groups: Group A (sildenafil group) were offered Sildenafil 20 mg t.i.d. with a plenty of fluids until delivery in addition to traditional treatment. Group B (Placebo group) received placebo drug with the same shape and texture as sildenafil citrate in addition to traditional treatment.Main outcome measures: Utero placental perfusion, fetal growth and maternal and fetal safety. Results: Sildenafil treatment was associated with a significant decrease of SBP between the two time points (P-value<0.001), a significant decrease of DBP between the two time points (P-value<0.001) and increase in estimated fetal weight by ultrasound (P<0.001). Conclusions: Despite limited data, overall there does not appear to be any severe adverse maternal side effects nor any increase in the rate of stillbirths, neonatal deaths attributed to SC.